GloGlo GTM brain

category

market profile

• text: GloGlo describes an early research pipeline, not an approved therapy, targeting immune structures implicated in several autoimmune conditions.
• text: Type 1 diabetes has established and investigational disease-modifying approaches, including Sanofi's teplizumab and competing cell therapies.

personas

• title: Biopharma business development leader
  pains:

  • Needs differentiated autoimmune programs with credible preclinical data
  • Must assess mechanism, safety and development risk before a partnership
• title: Autoimmune disease researcher or data holder
  pains:

  • Experimental validation and biological datasets limit hypothesis testing
  • Needs collaborators who connect computational models to relevant biology
• title: Endocrinologist or autoimmune specialist
  pains:

  • Patients need treatments that address disease without broad immune suppression
  • Wants rigorous evidence of safety and efficacy before clinical adoption

icp

• text: Potential research partners include academic immunology and type 1 diabetes groups with relevant biological data or experimental capabilities.
• text: Potential development partners include biopharma organizations investing in autoimmune therapeutics and biomarkers; no commercial customer profile is stated.

message pillars

• text: Design drugs aimed at the source of immune attack.
• text: Investigate a shared disease mechanism across autoimmune indications.
• text: Pursue selective therapies that preserve immune cells.
• text: Develop a biomarker alongside therapeutic programs.

objections

• objection: Is this treatment available or clinically proven?
  response: The website describes research and lab testing with future development milestones, not an approved drug; request current experimental evidence.
• objection: Can a selective approach preserve immune function while controlling disease?
  response: That is the stated research goal; it requires preclinical and clinical validation.

competitors

• name: Sanofi
  why: Markets teplizumab for delaying onset of stage 3 type 1 diabetes, a different disease-modifying approach.
• name: Vertex Pharmaceuticals
  why: Develops type 1 diabetes cell therapies, an alternative approach to the same disease.
• name: GentiBio
  why: Develops regulatory T-cell therapies for type 1 diabetes.

influencers

• name: Michael Fester
  url: https://www.linkedin.com/posts/michaelfester_i-dont-want-to-grow-old-with-type-1-diabetes-activity-7503544961028489216-Avbv
  why: Co-founder publicly discussing the motivation for type 1 diabetes research.
• name: Marie Schneegans
  url: https://www.linkedin.com/posts/marie-schneegans_weve-spent-the-last-few-weeks-running-hundreds-activity-7503141012564013056-a9Yz
  why: Co-founder discussing research, data needs and collaboration.

keywords

• type 1 diabetes drug discovery
• autoimmune disease therapeutics
• tertiary lymphoid structures autoimmune
• selective B cell therapy
• AI immunology drug discovery
• autoimmune biomarker development

voice

• mission-driven
• scientific
• hopeful

signals

• text: A research group has type 1 diabetes datasets or experimental capabilities and seeks computational collaborators.
• text: A biopharma team is sourcing early autoimmune programs or biomarkers for partnership.

hiring

• Founding Research Scientist
• Founding Machine Learning Engineer

pricing

motion

channels

• LinkedIn
• research partnerships
• website

confidence

Founders

• name: Marie Schneegans
  title: Founder
  role: Founder
  bio: co-founder GloGlo.com: curing autoimmune diseases with AI, starting with type 1 diabetes
• name: Michael Fester
  title: Founder
  role: Founder
  bio: Co-founder GloGlo.com. Previously, co-founder of Snips (AI voice platform, acquired by Sonos). Maths at Cambridge.